Zobrazeno 1 - 10
of 98
pro vyhledávání: '"Kazuo Noguchi"'
Autor:
Yohei Okada, Takeyuki Kiguchi, Taro Irisawa, Kazuhisa Yoshiya, Tomoki Yamada, Koichi Hayakawa, Kazuo Noguchi, Tetsuro Nishimura, Takuya Ishibe, Yoshiki Yagi, Masafumi Kishimoto, Hiroshi Shintani, Yasuyuki Hayashi, Taku Sogabe, Takaya Morooka, Haruko Sakamoto, Keitaro Suzuki, Fumiko Nakamura, Norihiro Nishioka, Tasuku Matsuyama, Satoshi Matsui, Takeshi Shimazu, Kaoru Koike, Takashi Kawamura, Tetsuhisa Kitamura, Taku Iwami
Publikováno v:
Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, Vol 28, Iss 1, Pp 1-9 (2020)
Abstract Background There is limited information on the predictive accuracy of commonly used predictors, such as lactate, pH or serum potassium for the survival among out-of-hospital cardiac arrest (OHCA) patients with hypothermia. This study aimed t
Externí odkaz:
https://doaj.org/article/c36489880d164244b526a42ebcc4aa11
Autor:
Yohei Okada, Takeyuki Kiguchi, Taro Irisawa, Kazuhisa Yoshiya, Tomoki Yamada, Koichi Hayakawa, Kazuo Noguchi, Tetsuro Nishimura, Takuya Ishibe, Yoshiki Yagi, Masafumi Kishimoto, Hiroshi Shintani, Yasuyuki Hayashi, Taku Sogabe, Takaya Morooka, Haruko Sakamoto, Keitaro Suzuki, Fumiko Nakamura, Norihiro Nishioka, Tasuku Matsuyama, Junya Sado, Satoshi Matsui, Takeshi Shimazu, Kaoru Koike, Takashi Kawamura, Tetsuhisa Kitamura, Taku Iwami, on behalf of the CRITICAL Study Group Investigators
Publikováno v:
Journal of Intensive Care, Vol 8, Iss 1, Pp 1-9 (2020)
Abstract Background We aimed to identify the association of pH value in blood gas assessment with neurological outcome among out-of-hospital cardiac arrest (OHCA) patients treated by extracorporeal cardiopulmonary resuscitation (ECPR). Methods We ret
Externí odkaz:
https://doaj.org/article/6a6a9492743e48ea98761b2fe47e0ae9
Autor:
Takayasu Kurata, Kazuhiko Nakagawa, Miyako Satouchi, Takashi Seto, Takeshi Sawada, Shirong Han, Masae Homma, Kazuo Noguchi, Naoyuki Nogami
Publikováno v:
Cancer Treatment and Research Communications, Vol 29, Iss , Pp 100458- (2021)
Introduction: Pembrolizumab plus chemotherapy significantly improved outcomes over chemotherapy alone as first-line treatment in patients with advanced non–small-cell lung cancer (NSCLC) in phase 3 international trials. In the phase 1 KEYNOTE-011 s
Externí odkaz:
https://doaj.org/article/c84021ef7ede4bc6954aa6dc78bbbeae
Autor:
Shunichi Sugawara, Kentaro Tanaka, Fumio Imamura, Nobuyuki Yamamoto, Makoto Nishio, Kyoichi Okishio, Tomonori Hirashima, Hiroshi Tanaka, Tatsuro Fukuhara, Yasuharu Nakahara, Takayasu Kurata, Nobuyuki Katakami, Morihito Okada, Hidehito Horinouchi, Hibiki Udagawa, Kazuo Kasahara, Miyako Satouchi, Hideo Saka, Takaaki Tokito, Yukio Hosomi, Keisuke Aoe, Kazuma Kishi, Kadoaki Ohashi, Takuma Yokoyama, Noriaki Adachi, Kazuo Noguchi, Paul Schwarzenberger, Terufumi Kato
Publikováno v:
Cancer Science.
Autor:
Isamu Okamoto, Tatsuo Ohira, Nobuyuki Yamamoto, Hidehito Horinouchi, Toyoaki Hida, Shinji Atagi, Tatsuro Fukuhara, Miyako Satouchi, Kazuma Kishi, Shunichi Sugawara, Shi Rong Han, Hideo Saka, Victoria Ebiana, Katsuyuki Hotta, Keisuke Aoe, Kazuhiko Nakagawa, Hiroshi Sakai, Hiroaki Okamoto, Kazuo Noguchi, Kaname Nosaki, Atsushi Horiike, Shigeki Umemura, Toshiaki Takahashi, Takayasu Kurata, Nobuyuki Katakami, Akimasa Sekine
Publikováno v:
Cancer Science
Cancer Sci
Cancer Sci
This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE‐024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non‐small‐cell lung cancer without EGFR/ALK alterations and a programmed death li
Publikováno v:
Bioscience, biotechnology, and biochemistry. 86(12)
The pharmacokinetics of novel formulations of curcumin mixed with squalene (CSQU) and of curcumin mixed with docosahexaenoic acid (CDHA) was investigated and compared with a standardized unformulated curcumin extract (StdC) and a solid lipid curcumin
Autor:
Taku Iwami, Haruko Sakamoto, Tetsuhisa Kitamura, Keitaro Suzuki, Tomoki Yamada, Tetsuro Nishimura, Tomotaka Sobue, Tasuku Matsuyama, Norihiro Nishioka, Yasuyuki Hayashi, Taku Sogabe, Hiroshi Kurosawa, Hiroshi Shintani, Takeshi Shimazu, Ryojiro Tanaka, Fumiko Nakamura, Satoshi Matsui, Takaya Morooka, Junya Sado, Taro Irisawa, Kazuo Noguchi, Yoshiki Yagi, Koichi Hayakawa, Takeyuki Kiguchi, Yohei Okada, Takuya Ishibe, Kazuhisa Yoshiya, Masafumi Kishimoto
Publikováno v:
International Heart Journal. 61:254-262
The effect of post-cardiac arrest care in children with out-of-hospital cardiac arrest (OHCA) has not been adequately established, and the long-term outcome after pediatric OHCA has not been sufficiently investigated. We describe here detailed in-hos
Autor:
Kazuo Noguchi, Takayasu Kurata, Takeshi Sawada, Kazuhiko Nakagawa, Shirong Han, Masae Homma, Takashi Seto, Naoyuki Nogami, Miyako Satouchi
Publikováno v:
Cancer Treatment and Research Communications, Vol 29, Iss, Pp 100458-(2021)
Introduction Pembrolizumab plus chemotherapy significantly improved outcomes over chemotherapy alone as first-line treatment in patients with advanced non–small-cell lung cancer (NSCLC) in phase 3 international trials. In the phase 1 KEYNOTE-011 st
Autor:
Marcus Eh Ong, Tetsuro Nishimura, Toshifumi Uejima, Takeshi Shimazu, Kazuo Noguchi, Makoto Matsuura, Tasuku Matsuyama, Taku Sogabe, Koichi Hayakawa, Yasuyuki Hayashi, Taro Irisawa, Takeyuki Kiguchi, Takaya Morooka, Mohamud Daya, Yasuyuki Kuwagata, Tetsuhisa Kitamura, Taku Iwami, Yoshiki Yagi, Fumiko Nakamura, Tomoki Yamada, Critical Study investigators, Kentaro Kajino, Kazuhisa Yoshiya, Masafumi Kishimoto
Publikováno v:
Geriatrics & Gerontology International. 19:1088-1095
Aim The purpose of this study was to evaluate the out-of-hospital cardiac arrest (OHCA) characteristics of patients stratified by age who had resuscitation attempted and were transported to tertiary emergency medical institutions in Osaka Prefecture,
Autor:
Hiroshige Yoshioka, Hiroshi Tanaka, Tatsuro Fukuhara, Terufumi Kato, Kazuhiko Yamada, Hiroshi Sakai, Miyako Satouchi, Kazuhiko Nakagawa, Masao Ichiki, Takashi Seto, Kazuo Kasahara, Makoto Nishio, Shi Rong Han, Toshiaki Takahashi, Takashi Shimamoto, Kazuo Noguchi
Publikováno v:
Cancer Science
Pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD‐1), has been shown to improve overall survival (OS) in patients with previously treated advanced non–small‐cell lung cancer (NSCLC) with programmed death ligand 1 (PD